Opdivo Could Boost Outcomes for People Battling Hodgkin Lymphoma
Dennis Thompson
TUESDAY, July 6, 2023 (HealthDay News) -- The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in…
Browsing Tag
Hodgkin
Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma
CHICAGO -- Adding the immune checkpoint inhibitor nivolumab (Opdivo), rather than brentuximab vedotin (Adcetris),…
Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma
Brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) after autologous…
Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Aging
NEW ORLEANS -- Survivors of childhood Hodgkin lymphoma experience accelerated epigenetic aging, with higher rates of…
Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2…
Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete response rate from 15 heavily pre-treated…
ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphoma
Investigational camidanlumab tesirine led to a high response rate in heavily pretreated patients with relapsed or refractory…
Family ties: Inherited genetic variants increase risk of Hodgkin lymphoma
Why did my child get cancer? Clinicians have longed for a way to help answer this question. Doctors knew Hodgkin lymphoma sometimes occurs in families, but why this happens has been a…
Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11…
Phase 1b clinical trial (ACTION) designed to evaluate TT11 as a potential second-line therapy TT11, Tessa’s autologous CD30-CAR-T therapy, is also being investigated as a monotherapy in…
Heart Disease or Cancer: Which is More Deadlier for Hodgkin Lymphoma Patients?
, a peer-reviewed journal of the American Cancer Society, reveals that people with early-stage HL are now at higher risk of dying from cardiovascular disease than from cancer.
…
Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma
A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in…